Amplify Trial Patient Recruitment To Commence In Early 2025
14/10/2024 14:07
Oct 14 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* POSITIVE GUIDANCE FROM THE U.S. FDA ON 64CU-SAR-BISPSMA
PHASE
III TRIAL IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER
* CLARITY PHARMACEUTICALS LTD - AMPLIFY TRIAL PATIENT
RECRUITMENT
TO COMMENCE IN EARLY 2025
Source text for Eikon: ID:nPn2KsxJRa
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial